The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Yocca Frank since 2018.
This trader's CIK number is 1733272.
At the time of last reporting, Yocca Frank was the Chief Scientific Officer of Bioxcel Therapeutics, Inc.. (stock ticker symbol BTAI).
Also see all insider trading activities at Bioxcel Therapeutics, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2025 | BTAI | 0 | $0 | 0 | $0 | 133 | $0 |
| 2024 | BTAI | 0 | $0 | 9,399 | $7,628 | 6,021 | $0 |
| 2023 | BTAI | 0 | $0 | 50,985 | $1,519,395 | 3,647 | $0 |
| 2021 | BTAI | 0 | $0 | 45,000 | $2,332,350 | 15,000 | $6,150 |
| 2020 | BTAI | 0 | $0 | 0 | $0 | 80,000 | $32,800 |
| 2018 | BTAI | 1,850 | $9,541 | 0 | $0 | 0 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2025-06-15 | BTAI | Option Ex | 35 | .00 | 0 |
| 2025-06-14 | BTAI | Option Ex | 33 | .00 | 0 |
| 2025-03-14 | BTAI | Option Ex | 31 | .00 | 0 |
| 2025-03-15 | BTAI | Option Ex | 34 | .00 | 0 |
| 2024-12-14 | BTAI | Option Ex | 521 | .00 | 0 |
| 2024-12-15 | BTAI | Option Ex | 562 | .00 | 0 |
| 2024-12-16 | BTAI | Sale | 430 | .35 | 151 |
| 2024-10-03 | BTAI | Sale | 7,175 | .55 | 3,946 |
| 2024-09-14 | BTAI | Option Ex | 521 | .00 | 0 |
| 2024-09-16 | BTAI | Sale | 355 | .69 | 244 |
| 2024-09-15 | BTAI | Option Ex | 563 | .00 | 0 |
| 2024-06-14 | BTAI | Option Ex | 521 | .00 | 0 |
| 2024-06-15 | BTAI | Option Ex | 562 | .00 | 0 |
| 2024-06-17 | BTAI | Sale | 372 | 1.28 | 476 |
| 2024-03-14 | BTAI | Option Ex | 521 | .00 | 0 |
| 2024-03-15 | BTAI | Option Ex | 2,250 | .00 | 0 |
| 2024-04-04 | BTAI | Sale | 1,067 | 2.63 | 2,811 |
| 2023-12-14 | BTAI | Option Ex | 521 | .00 | 0 |
| 2023-09-14 | BTAI | Option Ex | 521 | .00 | 0 |
| 2023-06-14 | BTAI | Option Ex | 521 | .00 | 0 |
| 2023-03-14 | BTAI | Option Ex | 2,084 | .00 | 0 |
| 2023-03-15 | BTAI | Sale | 985 | 19.69 | 19,395 |
| 2023-01-20 | BTAI | Sale | 50,000 | 30.00 | 1,500,000 |
| 2021-03-15 | BTAI | Sale | 15,000 | 48.88 | 733,275 |
| 2021-02-16 | BTAI | Sale | 15,000 | 58.53 | 877,950 |
| 2021-01-25 | BTAI | Option Ex | 15,000 | .41 | 6,150 |
| 2021-01-25 | BTAI | Sale | 15,000 | 48.08 | 721,125 |
| 2020-02-14 | BTAI | Option Ex | 80,000 | .41 | 32,800 |
| 2018-12-03 | BTAI | Buy | 450 | 5.23 | 2,353 |
| 2018-12-04 | BTAI | Buy | 450 | 5.20 | 2,338 |
| 2018-11-30 | BTAI | Buy | 450 | 5.20 | 2,339 |
| 2018-11-29 | BTAI | Buy | 500 | 5.02 | 2,511 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Yocca Frank (Chief Scientific Officer of Bioxcel Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.